Latest Medtech News

Rewardle Holdings Limited reported a 2.8% revenue increase to $9.68 million for FY24 but swung to a $3.44 million net loss, driven by rising expenses and associate losses. The company expanded its footprint with acquisitions in grocery delivery and fintech, while deepening its stake in AI-powered health tech partner CloudHolter.

Adherium Limited reports a robust 30% increase in US remote patient monitoring users and closes a $4.5 million capital raise, positioning itself for accelerated growth under new leadership.

Hydrix Limited reports steady June quarter revenues with a 10% rise from the prior quarter, supported by new contract wins and a robust $40 million project pipeline.

Rewardle Holdings has reinforced its strategic position by increasing its stake in CloudHolter following a $100 million capital raise, while progressing towards ASX relisting after resolving financial reporting delays.

Memphasys Limited has submitted its Felix™ sperm separation system for CE Mark approval, targeting Europe’s $5 billion IVF market, while expanding direct sales in Japan and validating its RoXsta™ oxidative stress diagnostic platform.

Adherium Limited has appointed seasoned medtech executive Dawn Bitz as CEO to spearhead the expansion of its Hailie® respiratory monitoring platform, with a strong focus on the US market.

Olympus Corporation has launched a nationwide emphysema screening campaign in the US powered by 4DMedical’s AI lung density analysis, marking a major commercial milestone for the Australian medtech firm.

Rewardle Holdings reported a strong March quarter with positive operational cash flow of $1.36 million, driven by its strategic partnership with MedTech firm CloudHolter, while progressing towards ASX relisting.

Hydrix Limited reports improved operating performance in Q3 FY25, buoyed by FDA clearance of its Gyder Surgical Hip Navigation system and a reduced cash operating loss, while managing tight liquidity with shareholder support.

Uscom Limited reported a 14% rise in Q3 customer receipts to $0.73 million, even as cash reserves dropped 38% to $1.34 million, reflecting increased operating costs and global market pressures.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.